ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive and founder Andrew Newland visits the Proactive London studio to speak with Thomas Warner after the liquid biopsy company announced what it calls "groundbreaking" clinical results from its latest research.
ANGLE's research focused on addressing cancer's progression and the challenges of evolving treatments. Newland explains that traditional oncology relies on tissue biopsy for targeted therapy, but this method becomes ineffective as cancer changes. ANGLE's solution involves analysing both circulating tumour DNA (from dead cancer cells) and living cancer cells in blood, using their Parsortix system. This novel approach allows for repeated non-invasive biopsies, providing critical information on cancer evolution and treatment efficacy.
Their study involved 47 patients with four cancer types (breast, lung, ovarian, prostate) and identified actionable cancer mutations in living cells, not found in dead cells. These findings could lead to more effective, personalised treatments, as many of these variants are targetable with existing FDA-approved drugs.
ANGLE's next steps involve commercialising this technology by offering services to pharmaceutical companies and publishing protocols for wider adoption. Their focus is on improving cancer patient outcomes through this innovative blood test method.
Additionally, ANGLE announced a significant contract with Eisai Inc., a large Japanese pharmaceutical company, to pilot their HER2 assay in clinical trials. This contract marks a major step in ANGLE's business growth and their commitment to advancing cancer treatment and diagnostics.
